The burden of norovirus disease in children: a multi-country study in Chile, Brazil, Thailand and the Philippines
Author
dc.contributor.author
Safadi, Marco Aurelio
Author
dc.contributor.author
Riera Montes, Margarita
Author
dc.contributor.author
Bravo, Lulu
Author
dc.contributor.author
Tangsathapornpong, Auchara
Author
dc.contributor.author
Lagos Zuccone, Rosanna Marietta
Author
dc.contributor.author
Thisyakorn, Usa
Author
dc.contributor.author
Linhares, Alexandre C.
Author
dc.contributor.author
Capeding, Rose
Author
dc.contributor.author
Prommalikit, Olarn
Author
dc.contributor.author
Verstraeten, Thomas
Author
dc.contributor.author
O'Ryan Gallardo, Miguel Luis
Admission date
dc.date.accessioned
2022-10-20T17:27:35Z
Available date
dc.date.available
2022-10-20T17:27:35Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
International Journal of Infectious Diseases 109 (2021) 77–84
es_ES
Identifier
dc.identifier.other
10.1016/j.ijid.2021.06.037
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/188727
Abstract
dc.description.abstract
Background: Noroviruses (NoVs) cause acute gastroenteritis (AGE) worldwide, affecting children in particular. We aimed to estimate the burden of disease due to NoV among children aged <6 years in Brazil, Chile, Philippines and Thailand. Methods: This was a prospective, hospital-based, observational study. Children were recruited over one year between 2014 and 2017. Four cohorts were analysed: community-acquired AGE outpatients and inpatients, nosocomial AGE inpatients, and asymptomatic outpatients. We collected demographic and clinical data, and a stool sample that was tested for NoV. Positive samples were tested for Rotavirus (RV) and NoV-genotyped. Disease severity was assessed by the Vesikari and modified Vesikari scores. Prevalence and incidence of NoV-AGE were estimated by cohort and country. Results: 1637 participants yielded valid laboratory results. The proportion of NoV-positive cases was 23.8% (95% CI 20.8-27.2) in the outpatient cohort, 17.9% (15.0-21.3) in the hospital cohort, 21.4% (12.7- 33.8) in the nosocomial cohort and 9.6% (6.9-13.2) in the asymptomatic cohort. Genotype GII.4 was predominant (58%). Less than 4% samples had RV coinfection. In general, NoV-positive subjects had more severe presentations than NoV-negative subjects. Conclusions: NoV caused AGE with substantial burden throughout the studied settings, with higher relative frequency in Brazil where RV vaccination coverage is high.
es_ES
Patrocinador
dc.description.sponsorship
Takeda Vaccines Inc.
ANID - Millennium Science Initiative Program IMII P09/016-F
ICN09_016
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
Elsevier
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States